New drug combo with radiation for advanced MSS colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced colorectal cancer that is MSS (microsatellite stable) and has spread beyond the colon.
- You have already tried at least two standard treatments (like chemo with 5-FU, oxaliplatin, irinotecan, Avastin, or Erbitux) and they stopped working or caused bad side effects.
- You can still perform your daily activities (ECOG score 0 or 1) and are expected to live at least 3 months.
- You have tumors that can be measured with scans.
- You have not had immunotherapy targeting PD-1, PD-L1, or CTLA-4 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving focused radiation (SBRT) together with fruquintinib and immune drugs (PD-1/CTLA-4) can control advanced, hard-to-remove colorectal cancer. It is for people whose cancer has grown despite standard first- and second-line chemotherapy.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a new combination of three treatments (a drug called QL1706, a targeted therapy called fruquintinib, and a short course of radiation) for people with colorectal cancer that has spread to the liver and has normal DNA repair. The goal is to see if this combination works better than the usual third-line therapy.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.